Anti-Heartburn Effects of Sugar Cane Flour: A Double-Blind, Randomized, Placebo-Controlled Study
- PMID: 32570710
- PMCID: PMC7353237
- DOI: 10.3390/nu12061813
Anti-Heartburn Effects of Sugar Cane Flour: A Double-Blind, Randomized, Placebo-Controlled Study
Abstract
Gastroesophageal reflux disease (GERD) affects approximately 20% of Australians. Patients suffer a burning sensation known as heartburn due to the movement of acidic stomach content into the esophagus. There is anecdotal evidence of the effectiveness of prebiotic sugarcane flour in controlling symptoms of GERD. This pilot study aimed to investigate the effectiveness of a prebiotic sugarcane flour in alleviating symptoms in medically-diagnosed GERD patients. This pilot study was a single center, double-blinded, placebo-controlled randomized trial conducted on 43 eligible participants. The intervention group (n = 22) were randomized to receive 3 g of sugarcane flour per day, and the control group (n = 21) received 3 g of cellulose placebo per day. Symptoms of gastroesophageal reflux disease were assessed before and after three weeks treatment using the validated Gastroesophageal Reflux Disease-Health Related Quality of Life questionnaire (GERD-HRQL). After three weeks there were significant differences in symptoms for heartburn, regurgitation, and total symptoms scores (p < 0.05) between the sugarcane flour and placebo. Mean GERD-HRQL scores increased in the placebo group for regurgitation (mean increase 1.7; 95% CI 0.23 to 3.2; p = 0.015) and total symptom scores (2.9; 95% CI 0.26 to 5.7; p = 0.033). In contrast, there were significant reductions in heartburn (mean decrease -2.2; 95% CI -4.2 to -0.14; p = 0.037) and total symptom scores (-3.7; 95% CI -7.2 to -0.11; p = 0.044) in the intervention group. This pilot study has shown significant positive effects of sugarcane flour in the reduction of GERD symptoms, and a larger randomized controlled trial is warranted.
Keywords: dietary fiber; gastroesophageal reflux disease; heartburn; regurgitation; sugarcane flour.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.J Integr Med. 2018 Mar;16(2):126-131. doi: 10.1016/j.joim.2018.02.008. Epub 2018 Feb 13. J Integr Med. 2018. PMID: 29526236 Clinical Trial.
-
Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.Aliment Pharmacol Ther. 2015 Oct;42(7):845-54. doi: 10.1111/apt.13334. Epub 2015 Jul 31. Aliment Pharmacol Ther. 2015. Retraction in: Aliment Pharmacol Ther. 2018 Nov;48(9):1039. doi: 10.1111/apt.15018. PMID: 26228097 Free PMC article. Retracted. Clinical Trial.
-
The Effect of Ramelteon on Heartburn Symptoms of Patients With Gastroesophageal Reflux Disease and Chronic Insomnia: A Pilot Study.J Clin Gastroenterol. 2016 Feb;50(2):e19-24. doi: 10.1097/MCG.0000000000000322. J Clin Gastroenterol. 2016. PMID: 25887111 Clinical Trial.
-
Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.Clin Ther. 2010 Apr;32(4):678-90. doi: 10.1016/j.clinthera.2010.03.020. Clin Ther. 2010. PMID: 20435237 Review.
-
Gastroesophageal Reflux Disease and Probiotics: A Systematic Review.Nutrients. 2020 Jan 2;12(1):132. doi: 10.3390/nu12010132. Nutrients. 2020. PMID: 31906573 Free PMC article.
Cited by
-
The Efficacy of Dietary Interventions in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Intervention Studies.Nutrients. 2024 Feb 5;16(3):464. doi: 10.3390/nu16030464. Nutrients. 2024. PMID: 38337748 Free PMC article.
-
Causal relationship between gut microbiota and risk of gastroesophageal reflux disease: a genetic correlation and bidirectional Mendelian randomization study.Front Immunol. 2024 Feb 21;15:1327503. doi: 10.3389/fimmu.2024.1327503. eCollection 2024. Front Immunol. 2024. PMID: 38449873 Free PMC article.
-
Role of microbial dysbiosis in the pathogenesis of esophageal mucosal disease: A paradigm shift from acid to bacteria?World J Gastroenterol. 2021 May 14;27(18):2054-2072. doi: 10.3748/wjg.v27.i18.2054. World J Gastroenterol. 2021. PMID: 34025064 Free PMC article. Review.
References
-
- Ronkainen J., Aro P., Storskrubb T., Lind T., Bolling-Sternevald E., Junghard O., Talley N.J., Agreus L. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population—The kalixanda study. Aliment. Pharmacol. Ther. 2006;23:1725–1733. doi: 10.1111/j.1365-2036.2006.02952.x. - DOI - PubMed
-
- Miller G., Wong C., Pollack A. Gastro-oesophageal reflux disease (gord) in australian general practice patients. Aust. Fam. Physician. 2015;44:701. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical